US Clinical Practice Experience with Eculizumab in Myasthenia Gravis: Acute Clinical Events and Healthcare Resource Utilization
Abstract Background and Objective The terminal complement inhibitor eculizumab is approved in the USA for the treatment of patients with acetylcholine receptor antibody-positive generalized myasthenia gravis (MG). The ELEVATE study aimed to examine clinical-practice outcome data on eculizumab effect...
Saved in:
Main Authors: | Richard J. Nowak (Author), Ali A. Habib (Author), Andrew J. Klink (Author), Srikanth Muppidi (Author), Anju Parthan (Author), S. Chloe Sader (Author), Alexandrina Balanean (Author), Ajeet Gajra (Author), James F. Howard (Author), ELEVATE Study Group (Author) |
---|---|
Format: | Book |
Published: |
Adis, Springer Healthcare,
2024-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A Critical Examination for the Pricing of Eculizumab and Efgartigimod in Myasthenia Gravis
by: Paul C. Langley
Published: (2021) -
Myasthenia Gravis-Directed Clinical Evaluation
by: Savneet Kaur, et al.
Published: (2022) -
Prognosis of Myasthenia Gravis
by: J Gordon Millichap
Published: (1992) -
Neonatal Myasthenia Gravis
by: J Gordon Millichap
Published: (1988) -
Maintenance Therapy for Myasthenia Gravis
by: J Gordon Millichap, et al.
Published: (2014)